Pioneering Regenerative Medicine
Without Immunosuppression
Pioneering Regenerative Medicine
Without Immunosuppression
iTOL-100:
Biotechnology-Derived Protein Inducing
Immune Tolerance Platform
iTOL-100 is a synthetic form of the naturally occurring protein, FasL, combined with a synthetic hydrogel microparticle (microgel) that allows convenient and effective co-administration with implanted cells or organoids to induce local immune tolerance without the need for life-long immunosuppression.
iTOL-100:
Biotechnology-Derived Protein Inducing
Immune Tolerance Platform
iTOL-100 is a synthetic form of the naturally occurring protein, FasL, combined with a synthetic hydrogel microparticle (microgel) that allows convenient and effective co-administration with implanted cells or organoids to induce local immune tolerance without the need for life-long immunosuppression.
Developing a Potential Cure for Type 1 Diabetes
Our lead program iTOL-101 is being developed as a potential cure for Type 1 Diabetes. Using our proprietary biotechnology-derived protein therapy platform, iTOL-100, allogenic pancreatic islets are co-implanted and in preclinical studies have shown immune acceptance and long-term function of the graft with control of blood glucose levels and restoration of insulin secretion. Our follow-on candidate, iTOL-102 is leveraging significant advancements in stem cells, which allows an inexhaustible supply of insulin-producing cells for use in Type 1 Diabetes.
Development Pipeline
Email Alerts:
Have the latest news and information delivered directly to your inbox
Get in Touch with us:
Please reach out with any questions
News:
iTolerance, Inc. Strengthens Leadership Team with Key Appointments to Advance Regenerative Medicine Platform
Dennis M. Hester, Ph.D., an accomplished biotech professional with over 30 years of experience in regulatory affairs, quality assurance and product development, appointed as Senior Vice President, Chemistry, Manufacturing and ControlsSumitra M. Ghate, a proven...
iTolerance, Inc. Announces Formation of Scientific Advisory Board with Appointment of International Leaders in Immune Tolerance Discoveries
- Inaugural appointments include scientific founders of iTolerance's regenerative cell therapy pipeline with expertise across biomaterials, immune modulators, and pancreatic islet transplantation for Type 1 Diabetes- Company advances pioneering regenerative cell...
Email Alerts:
Have the latest news and information delivered directly to your inbox
Get in Touch with us:
Please reach out with any questions
News:
iTolerance, Inc. Strengthens Leadership Team with Key Appointments to Advance Regenerative Medicine Platform
Dennis M. Hester, Ph.D., an accomplished biotech professional with over 30 years of experience in regulatory affairs, quality assurance and product development, appointed as Senior Vice President, Chemistry, Manufacturing and ControlsSumitra M. Ghate, a proven...
iTolerance, Inc. Announces Formation of Scientific Advisory Board with Appointment of International Leaders in Immune Tolerance Discoveries
- Inaugural appointments include scientific founders of iTolerance's regenerative cell therapy pipeline with expertise across biomaterials, immune modulators, and pancreatic islet transplantation for Type 1 Diabetes- Company advances pioneering regenerative cell...
iTolerance, Inc., a Company Pioneering Regenerative Medicine Without Immunosuppression, Announces Leadership Team
Company advancing regenerative cell therapy platform technology with broad utility toward first-in-man study Lead product candidate, ITOL-101, for the treatment of Type 1 Diabetes entering IND-enabling studies Anthony Japour, M.D., a seasonedbiotech and pharmaceutical...